Pharmacist Registration in Canada and Australia with a Foreign Degree 2026

How does the Pharmacy Examining Board of Canada assess a foreign pharmacy degree?

In four steps, in a fixed order. You enrol with Pharmacists’ Gateway Canada, run by the National Association of Pharmacy Regulatory Authorities, and receive a National Identifier Number. Only then does the Pharmacy Examining Board of Canada accept a Document Evaluation, at CAD 715 on its 2026/2027 schedule. After that come the two parts of the Qualifying Examination.

The Board is explicit about the limit of what it does. Its own Document Evaluation page states that certification by the Board does not guarantee eligibility with a provincial regulatory authority, and that it does not itself require language testing — the provinces do. That single sentence explains most of the confusion pharmacists arrive with. The Board certifies. A province licenses.

Document Evaluation is valid for five years. Pass Qualifying Examination Part I inside that window and it stops expiring; miss it and the evaluation has to be redone. Small detail, real consequence.

What changes in Canada when the Pharmacist Evaluating Examination ends in October 2026?

The screening exam disappears. The Board states that the October 2026 administration is the last administration of the Pharmacist Evaluating Examination, sat on 15 October 2026 with results on 5 November 2026. From that point the international-graduate route runs from Document Evaluation directly into Qualifying Examination Part I, with no intermediate knowledge screen.

It is worth knowing what is being retired. The Evaluating Examination carried 140 questions in two sections of 70, ninety minutes each, inside a computer-based sitting of 3 hours 15 minutes including orientation. Its blueprint, effective June 2025, split the paper into pharmacy practice at 55 per cent, pharmaceutical sciences at 25 per cent and behavioural, social and administrative sciences at 20 per cent. Pass standing required 60 per cent of the 140 available points.

The Board also published how candidates did on it. Across seven sittings between Winter 2021 and Winter 2024, 4,735 first-time candidates passed at 36.2 per cent and 2,601 repeat candidates at 38.4 per cent. Those numbers describe a screen that was doing real filtering work. Removing it does not lower the standard; it moves the whole assessment burden onto the Qualifying Examination, which is where the standard was always set.

What does the Australian Pharmacy Council require from an overseas pharmacist in 2026?

An eligibility check first, then one written exam, then a document for the visa file. The Council sorts candidates into streams. A pharmacist who graduated outside Australia, Canada, Ireland, New Zealand, the United Kingdom or the United States enters the Knowledge Stream and sits the Overseas Pharmacist Readiness Assessment. A pharmacist registered in Canada, Ireland, the United Kingdom or the United States enters the Competency Stream and sits the CAOP exam instead.

The Knowledge Stream has a degree-length rule with a date in it: four years of full-time academic study if the qualification was completed after 1 January 2006, three years if it was completed before that date. The eligibility check costs AU$810 in 2026 and is non-refundable. The Council states it aims to respond within five working days of receiving complete documentation, asks candidates to allow up to four weeks, and advises lodging at least eight weeks before a registration window closes. There is no expiry on the eligibility check itself.

OPRA replaced the Knowledge Assessment of Pharmaceutical Sciences. The Council announced that November 2024 was the last KAPS sitting and March 2025 the first OPRA sitting, with revised content areas, a shorter exam and Rasch-model scoring. That transition is done. Anyone still searching for KAPS in 2026 is searching for an exam that no longer runs.

OPRA itself is 120 multiple-choice questions in 150 minutes, closed book, at approved test centres, at AU$2,245 per attempt in 2026. The Council’s exam guide dated 30 July 2026 notes that 90 per cent of the questions are scored and 10 per cent are unscored trial items, and that scaled scoring is used across versions. There is no cap on resits. The pass standard is defined as the minimum needed to apply for provisional registration as an intern pharmacist — which tells you exactly where the exam sits in the chain.

How do the two systems differ structurally, not just in price?

One difference outranks the rest. Canada splits assessment between a national certifier and provincial licensors; Australia runs one national assessment body feeding one national board. Everything else — where the clinical exam sits, who sets the language rule, whether a licensing document also serves a visa — follows from that.

The second structural difference is where performance is tested. Canada puts the objective structured clinical examination inside the certification body’s own process: 11 scored stations, 9 interactive with simulated participants and assessors, 2 non-interactive, 7 minutes each, with candidates at the centre for roughly six and a half hours. Australia has no equivalent at Council stage. Performance there is assessed after the intern year, by the Pharmacy Board of Australia’s written and oral examinations, which must be passed within 18 months of each other.

The third is the visa link. The Australian Pharmacy Council sells a Skills Assessment Outcome for AU$300 whose stated purpose is to support a visa application, valid for three years. Canada has no such artefact. A pharmacist’s Canadian licensing file and Canadian immigration file are simply two different files with two different owners, which is why they can be run at the same time. If you want that sequencing mapped against your own dates, Medschool Experts covers it in a free consultation.

What do the published pass rates actually show?

They show a wide spread by candidate group, and they exist for only one of the two countries. The Pharmacy Examining Board of Canada publishes a table titled “Performance Trends on the Pharmacist Qualifying Examination” covering administrations from May 2024 to May 2026, broken down by subgroup. The Australian Pharmacy Council publishes no comparable figure.

Read the Canadian table carefully and two things stand out. International first-time candidates passed Part I at 35.6 per cent and Part II at 56.6 per cent. International repeat candidates passed Part I at 47.1 per cent and Part II at 69.8 per cent — higher, not lower, than first-timers. That inversion is unusual in examination statistics and says something plain: candidates who sit again after knowing the format do better on both parts.

The reference group is defined narrowly, and the definition matters. It is graduates of Canadian-accredited pharmacy programmes sitting for the first time in their year of graduation, at 87.2 per cent for Part I and 92.5 per cent for Part II. The comparison is between a fresh domestic cohort and an international cohort whose degrees, in many cases, were finished years earlier in another language of instruction. The examination is criterion-referenced, not ranked against a quota, so nothing about those percentages caps how many international candidates can pass in a given year.

Australia’s side of the ledger is volume, not outcome. The Council’s 2024–25 annual report records 5,401 completed eligibility checks, against 4,279 in 2023–24, 2,638 in 2022–23 and 1,225 in 2021–22, plus 6,805 exam sittings and candidates from 85 countries, against 72 the year before. India, the Philippines, Egypt and Pakistan were among the largest source countries. Volumes climbed sharply. What it does not tell you is how many passed.

How long does each route take, month by month?

Plan in seasons, not weeks, and anchor to the exam windows the two bodies publish. Both regulators run their sittings twice a year, and both put the application deadline several months ahead of the exam. That gap is what actually sets the calendar — not preparation time. Book backwards from the deadline.

Two deadlines from 2026 show how far ahead the paperwork sits. The Pharmacy Examining Board of Canada closed applications for its November 2026 Qualifying Examination on 6 August 2026, three months before the exam, and opened applications for the February 2027 sitting on 28 August 2026 with a deadline of noon Eastern Time on 19 November. The Australian Pharmacy Council closed OPRA registration for the November 2026 sitting on 19 October 2026, five weeks before the exam, but expects the eligibility check to have been lodged eight weeks before that.

What does each route cost, and what does the arithmetic look like?

Central-body fees are knowable and published. Everything downstream — provincial registration, Ahpra registration, language tests, visas, travel — is set by other bodies and does not appear on either fee page. So the honest budget has two layers, and only the first can be added up from primary sources. Two layers, not one.

Worked example, Australia, Knowledge Stream, central-body fees only. Eligibility check AU$810, plus OPRA at AU$2,245, plus the Skills Assessment Outcome at AU$300, gives AU$3,355. Add the Intern Written Exam at AU$790 and the running total is AU$4,145. One unsuccessful OPRA attempt adds another AU$2,245, taking it to AU$6,390. If the skills assessment lapses before the visa is granted, an updated skills assessment at AU$610 brings it to AU$7,000. Appeals cost nothing, which is worth knowing before paying for a resit.

Worked example, Canada, international graduate, central-body fees only. Document Evaluation CAD 715, plus Qualifying Examination Part I at CAD 870, plus Part II at CAD 1,950, gives CAD 3,535. One repeat of Part I adds CAD 870 for CAD 4,405. A hand re-score of Part II adds CAD 200 for CAD 4,605. A single rescheduled sitting adds CAD 60 plus harmonised sales tax.

Do not convert one total into the other. The two figures answer different questions: AU$4,145 buys an assessment plus a migration document plus one of the two Australian registration exams, while CAD 3,535 buys certification only, with the provincial licence still ahead. Comparing them as though they were the same purchase is the most common error in cost write-ups of these two systems.

How does immigration work alongside licensing in each country?

In Australia the two files are stapled together; in Canada they are not. The Australian Pharmacy Council issues the Skills Assessment Outcome specifically so it can be lodged with a visa application, and it states plainly that completing a skills assessment does not guarantee a visa, sponsorship, registration or employment. The Department of Home Affairs alone decides the visa.

The Council groups the realistic visa routes into four: family visas, student visas, sponsored visas requiring an employer’s job offer, and state-nominated visas allocated by individual states and territories with a limited number of places each year. State nomination adds its own occupation-list criteria, which the Council notes vary by state and can include work experience, Australian general registration and evidence of funds. Points-tested routes are scored on age, education, work experience, funds and English, using the Department’s own calculator. Occupation lists and point thresholds are reset by the Department, not by the Council, so check them on the day you lodge. On timing the Council is blunt: obtaining a visa can take from a few months to over a year.

Canada runs the two tracks in parallel by design. Different owners, different clocks. Nothing the Pharmacy Examining Board of Canada issues functions as an immigration document. That independence is an advantage if it is used deliberately: a Document Evaluation submitted while a residence application is still in the federal system does not wait for it. It turns into a problem only when the evaluation’s five-year validity quietly runs down during an immigration process, which is the scenario worth diarising from day one.

Marina, who advises Medschool Experts clients on visa and immigration law from Belgrade, sees the same pattern in both directions: the licensing calendar is fixed by exam windows and the immigration calendar is not, so the licensing dates should be booked first and the immigration file built around them. Read how other healthcare graduates sequenced the two in their own accounts.

What do shorter comparisons of these two countries usually leave out?

Four things, and each of them changes a plan. The first is that Canadian certification is not a Canadian licence. The Board says so on its own page. The provincial regulatory authority sets the language requirement, the structured practical training and the jurisprudence component, and those provincial steps sit after everything described above — which is where most of the real elapsed time lives.

The second is the resit arithmetic, which runs in opposite directions. The Australian Pharmacy Council allows unlimited OPRA attempts but the Skills Assessment Outcome expires after three years, so time pressure comes from the document, not the exam. The Pharmacy Examining Board of Canada does not cap attempts in the same public way but requires both parts of the Qualifying Examination to be passed within three years of each other, so the pressure comes from the gap between two exams.

The third is that only one country publishes outcomes. If you want to know how a cohort like yours performs, Canada tells you and Australia does not. Volume figures from the Council’s 2024–25 annual report are not a substitute.

The fourth is currency. Nobody is charging you in a shared unit, and a headline “total cost” that blends CAD and AUD through a spot rate from an unnamed date is not a figure — it is a guess dressed as one. Two budgets. Two calendars. Medschool Experts maps both against a real profile in a free consultation.